Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRICE pembrolizumab dose-optimization study in non-small cell lung cancer
jRCTs031230682Recruiting
- Sponsor
- Public Health Research Foundation
- Start
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Public Health Research Foundation. Primary endpoint: Progression-free survival. Started Apr 2024; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031230682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230682.